The European Medicines Agency accepted Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA) Marketing Authorization Application for Hetlioz to treat non-24-hour sleep-wake disorder sending the stock price soaring $2.54 to close at $12.56.
EMA accepts Vanda's MAA
June 04, 2014 at 17:30 PM EDT
